Risk factors associated with precancerous cervical lesion among women screened at Marie Stops Ethiopia, Adama town, Ethiopia 2017: a case control study

Roza Teshome Kassa*

Abstract

Objective: Although cervical cancer is a preventable disease, it remains a leading cause of death among women in developing countries. In this unmatched case control design, 55 cases and 109 controls were included. The main objective of this study was to assess the risk factors of precancerous cervical lesion in Adama town.

Results: A total of 164 participants were recruited in this study. Of the 109 controls, 64 (61%) and 41 (39%) of cases were using oral contraception. Women who were using oral contraception were two times at risk for developing precancerous cervical lesion than who were not using (COR = 2.059 95% CI 1.006, 4.216; AOR = 2.342). Out of 55 cases, 21 (38.2%) cases had a history STI and out of 109 controls, 24 (22.2%) controls had a history of STI. It was revealed that STI has a significant association for developing of precancerous lesion. Women who had a history of STI were two times at risk of developing precancerous cervical lesion than who had no (COR = 2.187; AOR = 2.485). It was found that initiation of sexual intercourse before the age of 15 years has 5.6 risks to develop precancerous cervical lesion (COR = 5.625 AOR = 6.703).

Keywords: Precancerous cervical lesion, Case control, VIA, Cervical cancer, Ethiopia

Introduction

Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors [1]. Developing countries contribute more than three-quarter of women death in cervical cancer every year and Ethiopia contributes substantially to this figure due to inadequate health care and virtually nonexistent screening mechanisms for early detection [2]. According to 2008 estimates, invasive cervical cancer (ICC) is the second most common cancer in women worldwide. Although cervical cancer is a preventable disease, it remains a leading cause of death among women in developing countries. In 2012 there were an estimated 528,000 new cases of cervical cancer and 266,000 deaths from cervical cancer, with 70% of those deaths occurring in developing countries [3].

In Africa, according to most recent estimates, 80,400 women are diagnosed with cervical cancer every year, the second most frequent cancer. 50,300 die from the disease every year, the leading cause of cancer death. In sub-Saharan Africa, cervical cancer accounts for 22.5% of all cancer cases in women, and the majority of women who develop cervical cancer live in rural areas [3, 4].

Of nearly 22 million Ethiopian women over the age of 15, approximately 7600 are diagnosed with cervical cancer and roughly 6000 women die of the disease each year. On the other hand, the incidence and mortality from cervical cancer in Ethiopia is 26.4 and 18.4/100,000 respectively. These figures are probably lower than the actual number of cases, given the low level of awareness, cost, and limited access to screening services and lack of a national cancer registry [4, 5].
Human papilloma virus (HPV) is the primary etiologic agent of cervical cancer. It is the most common viral infection of the reproductive tract. Most sexually active women and men will be infected at some point in their lives and some may be repeatedly infected. The peak time for acquiring infection for both women and men is shortly after becoming sexually active. It is responsible for 99% of cervical cancer and accounts for approximately half of the infection related burden of cancer in women. There are over 100 types of HPV. The genital-type HPVs are divided into high, intermediate and low-risk types according to their association with genital tract cancer. High risk types of HPV (HPV-16, -18, -31, -45) account for more than 90% of cervical carcinoma [6].

Several screening methods to detect precancerous and cancer are available, and can be performed safely and inexpensively in an outpatient setting. In many developing countries, treatment of precancerous is neglected because therapeutic services are unavailable, inaccessible, or inadequately linked to screening services.

The high burden of cervical cancer combined with the lack of infrastructure and financial resources for cytology based screening programs has led to the search for alternative strategies for cervical cancer prevention in low-resource settings [7]. The most widely implemented low-cost screening technique is visual inspection with 3–5% acetic acid (VIA) [8].

Main text

Methods

The study was conducted in Adama town, Marie Stops International Hospital. An institutional based retrospective case control design was conducted. The sample size of this unmatched case–control study was calculated by using Stat cal in epi-info 7 by the following assumptions. Level of confidence 95, 80% power, proportion of controls who begun sexual intercourse before the age of 20 year odds ratio of 60% for the development of precancerous lesions of the cervix [17], Odds ratio 3 and case to control ratio 1:2. This gives the total sample size of 164 individuals: 55 cases and 109 controls.

Structured data abstraction form was developed after reviewing the client record/log book and literatures. Fifty-five cases were identified by registration identification number and included in the study. The next two controls were included consecutively. For any missed data of control the next serial number was included. Ethical approval was obtained from the ethical review board of the Rift Valley University. Client records were treated confidentially and name of clients was not included in the data collection. Data was entered, cleaned and analyzed by SPSS version 20 statistical package. Descriptive summaries using frequencies and proportions were used to present the study results. Binary and multivariable logistic regressions were used to identify factors associated with the pre-cancerous cervical lesion. Adjusted odds ratio at 95% confidence interval and P-value were used to measure the strength of association and identify statistically significant result. P-value < 0.05 was considered as a statistically significant association.

Results

Socio demographic characteristics

One hundred and sixty-four participants were recruited in this study. From these, 109 were controls who were VIA negative and 55 were cases who were VIA positive. The mean age was 35.7 years. Most of the controls 104 (68.9%) were married and 47 (31.7%) of cases were married. Of control groups, 14 (12.8%) and 3 (5.5%) of cases were uneducated (Table 1).

Reproductive health history

Among the control group, 105 (96.3%) and 53 (96.4%) of cases had children. Of these, 96 (91.4%) of controls and 50 (94.3%) of cases had less than four children while 9 (8.6%) of controls and 3 (5.7%) cases had more than 4 children. More than half of the controls, 64 (58.7%) and 41 (74.5%) of cases were using contraception. From the control group, 24 (22%) and 21 (38.2%) of cases had a history STIs (Table 2).

Among total study subjects 45 (27%) had first sexual intercourse before the age of 15 years. Out of total participants, 55 (33.5%) had more than five sexual partners in their lifetime. The majority of participants, 124 (75.6%) were tested for HIV/AIDS. Of these, 107 (65.2%) of them

| Table 1 Socio demographic characteristics, case control study, Marie Stops Ethiopia, Adama, 2017 |
| Variables | Cases (%) | Controls (%) |
| --- | --- | --- |
| Age (years) | | |
| 30–40 | 48 (87.2) | 96 (88.1) |
| 40–60 | 6 (10.9) | 11 (10.1) |
| > 60 | | 1 |
| Level of education | | |
| Elementary | 12 (21.8) | 25 (22.9) |
| High school | 30 (54.5) | 37 (33.9) |
| College | 10 (18.2) | 33 (30.3) |
| None | 3 (5.5) | 14 (12.8) |
| Marital status | | |
| Married | 53 (96.4) | 101 (92.7) |
| Divorced | 2 (3.6) | 6 (5.5) |
| Widowed | 0 | 1 |
| Single | 0 | 1 |
were HIV negative 18 (11%) of them were HIV positive (Table 2).

**Risk factors associated with precancerous cervical lesion**

Of the 55 cases, 41 (74.5%) of them had been using oral contraceptives. Out of 109 controls, 64 (58.7%) of them had been using oral contraception. It was found that there is a significant association between using oral contraception and developing precancerous cervical lesion. Women who were using oral contraception were two times at risk for developing of precancerous cervical lesion than who were not using (COR = 2.059; 95% CI 1.006, 4.216; AOR = 2.342; P < 0.025) (Table 3).

Out of 55 cases 21 (38.2%) cases had a history STI and out of 109 controls, 24 (22.2%) controls had a history of STI. It was revealed that STI has a significant association for developing of precancerous lesion. Women who had a history of STI were two times at risk of developing precancerous cervical lesion than who had no history of STI (COR = 2.187; 95% CI 1.078, 4.440; AOR = 2.485; P < 0.015) (Table 3).

Of the 55 cases 53 of them had children and 3 (5.7%) had more than 4 children. Out of 109 controls, 105 of them had children and 9 (8.6%) of them had more 4 children. It was found that there was no significant association between increasing number of children and developing precancerous cervical lesion after even adjusting other confounding factors (COR = 0.643; 95% CI 0.166, 2.470; AOR = 0.455; P < 0.280) (Table 3).

Out of 55 cases 25 (45.5%) cases, had first sexual intercourse at the age of less than 15 years and out of 109 controls 20 (18.3%) had first intercourse at the age of less than 15 years. It was found that initiation of sexual intercourse before the age of 15 years has 5.6 risks to develop precancerous cervical lesion (COR = 5.625; 95% CI 1.9245, 16.271; AOR = 6.703; P < 0.001) (Table 3).

Among 109 controls 23 (21.1%) had more than five sexual partners in their lifetime, whereas from 55 cases 32 (58.2%) of them had more than five sexual partners in their lifetime. It was revealed that having more five sexual partners has six times risk to develop precancerous cervical lesion (COR = 6.121; 95% CI 2.818, 13.294; AOR = 5.864; 95% CI 2.677, 12.843; P < 0.00) (Table 3).

**Discussion**

This study showed that use of oral contraception increases precancerous cervical lesion by twofolds (COR = 2.059; 95% CI 1.006, 4.216; AOR = 2.342; P < 0.025). The possible association between the use of OCP and the development of cervical neoplasia has been the subject of many epidemiological investigations, but the nature of the association remains unclear [9]. In 1993 a massive worldwide study conducted by the World Health Organization, was published which examined the risk established between OCP use and invasive squamous cervical carcinoma among 2300 women who had cervical carcinoma and found a strong correlation [10]. In a large study group, Herrero et al. showed that women who had received injectable progestins for at least 5 years and who had used them at least 5 years ago suffered a 430% increased risk of developing cervical cancer [11]. Also, Briton revealed that usage of OCP for more than 10 years could increase the risk of cervical cancer [12].

In this study, initiation of sexual intercourse earlier than the age of 15 years has 5.6 times risk for the development of precancerous cervical lesion. Similar finding was observed in a study conducted in Jimma, Ethiopia that showed clients who started intercourse less than 16 years were 2.2 times more likely to have a precancerous cervical lesion (AOR [95% CI] 2.2 [1.1, 4.3]) [13]. This association was also seen in a case–control study of cervical cancer risk factors in Indian women where the maximum risk of cervical cancer was increased in women with a sexual debut at < 12 years old (OR = 3.5) and also increased in women who had extramarital sexual relationships (OR = 5.5) [14]. This may be due to Women who had sexual intercourse for the first time at a younger age.

### Table 2 Reproductive health history of study participants, Marie Stops Ethiopia, Adama, 2017

| Variables                        | Cases (%) | Controls (%) |
|----------------------------------|-----------|--------------|
| Current use of contraception     | 41 (39)   | 64 (61)      |
| History of STI                    | 21 (46.7) | 24 (53.3)    |
| Number of children                |           |              |
| < 4 children                      | 50 (34.2) | 96 (65.8)    |
| > 4 children                      | 3 (25)    | 9 (75)       |
| Age of first sexual intercourse   |           |              |
| < 15                              | 20 (55.6) | 25 (44.4)    |
| 16–20                            | 23 (29.1) | 56 (70.9)    |
| 21–25                            | 6 (18.2)  | 27 (81.8)    |
| > 26                             | 1 (14.3)  | 6 (85.7)     |
| No of sexual partner in lifetime  |           |              |
| One                              | 15 (18.5) | 66 (81.5)    |
| 2–5                              | 8 (28.6)  | 20 (71.4)    |
| > 5                              | 32 (58.2) | 23 (41.8)    |
| HIV/AIDS tested                   |           |              |
| Yes                              | 42 (33.9) | 82 (66.1)    |
| No                               | 12 (32.9) | 27 (67.5)    |
| HIV/AIDS result                   |           |              |
| Positive                         | 9 (50%)   | 9 (50)       |
| Negative                         | 33 (30.8) | 74 (69.2)    |
| On art                           |           |              |
| Yes                              | 5 (50)    | 5 (50)       |
| No                               | 4 (50)    | 4 (50)       |
age may have been exposed to a persistent HPV infection for longer periods compared to women who began to have sex at a later age [15].

In the present study there was a strong association between sexual transmitted infections with precancerous cervical lesion (COR = 2.187; 95% CI 1.078, 4.440; AOR = 2.485; P < 0.015). Similarly, in a study conducted in Aksum, Ethiopia there was a strong association between STI and the development of cervical cancer [AOR = 49.88 (95% CI 16.59, 149.91)] [16]. This study found that having multiple sexual partner and precancerous cervical lesion has a strong association. This was a comparable finding with a study conducted in Rwanda that found multiple sexual partner is a risk factor for cervical cancer (COR = 1.40; 95% CI 0.85–2.30) [17]. This association of cervical cancer with sexual behavior also was shown in a case–control study done in Manchester, England where the number of sexual partners was the risk factor (OR for six or more = 3.89) [18]. This may be due to; sexual activity may increase the chance of transmission of the human papilloma virus (HPV). The probability of encountering an infected partner increases as the number of partners someone has increased. On the other hand, having fewer sexual partners means there are simply fewer chances to come into contact with someone who has HPV infection.

Conclusion
The majority of women who develop a precancerous cervical lesion tend to have one or more identifiable factor that increases the risk of the disease. Use of current oral contraception has 2 times risk for precancerous cervical lesions. Being infected with STIs, first intercourse at an early age and multiple sexual partners in lifetime are also independent predictors of precancerous cervical lesions. So that it should be focused on addressing HPV vaccination for girls, avoiding early marriage, promoting use of condom and discouraging initiation of early sexual intercourse (Additional file 1).

Limitation
- Being a retrospective record review design was the limitation of this study. Data collectors faced challenges in skipping incomplete recorded client cards.
Additional file

Additional file 1. Risk factors of precancerous cervical lesion file.

Abbreviations
CIN: cervical intraepithelial lesion; LSIL, HSIL: low grade and high grade squamous intraepithelial lesion; HPV: human papilloma virus; HIV: human immunodeficiency virus; ICC: invasive cervical cancer; WHO: World Health Organization; HAART: highly active antiretroviral therapy; VIAC: visual inspection of the cervix with acetic and cervicography; LEEP: loop electrosurgical excision procedure; ART: antiretroviral therapy; OICs: opportunistic infectious conditions clinics; ZDHS: Zimbabwe Demographic Health Survey.

Authors’ contributions
RT planned, designed the study, collected data, did statistical analysis and wrote the manuscript. The author read and approved the final manuscript.

Acknowledgements
I would like to extend my deepest gratitude to Marie Stops International Hospital staffs and data collectors.

Competing interests
The author declares that she has no competing interests.

Availability of data and materials
All raw data were provided.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was conducted after obtaining ethical clearance from ethical review board of the Rift Valley University. A letter of consent was obtained from Marie Stops Hospital to review clients’ card. Client records were treated confidentially.

Funding
Financial and material support were obtained from Rift Valley University.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 23 September 2017 Accepted: 10 February 2018
Published online: 20 February 2018

References
1. Berek JS, editor. Berek and Novak’s gynecology. 14th ed. Stamford: Lipincott Williams & Wilkins, 2007.

2. Loutfi A, Pickering JL. The distribution of cancer specimens from two pathology centers in Ethiopia. Ethiop Med J. 1992;30:13–7.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008. Globocan 2008. Int J Cancer. 2010;127(12):2893–917. https://doi.org/10.1002/ijc.25516.
4. WHO/ICO information centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in Ethiopia. 2007. https://www.who.int/htp/vcentre.
5. UNFPA partnership for child and new born african women development fund. Africa Cervical Cancer Multinational Incidence&Mortality Scorecard 2014 available: http://www.who.int/prmnch/media/events/2014/africa_cancer_mortality.pdf.
6. Sairaf M, Mohamed FA. Knowledge, attitudes, and practice related to cervical cancer screening among Kuwaiti women. Med Princ Pract. 2009;18(1):35–42.
7. Denny L. Cervical cancer prevention: new opportunities for primary and secondary prevention in the 21st century. Int J Gynaecol Obstet. 2012;119(Suppl 1):S80–4.
8. Bradford L, Goodman A. Cervical cancer screening and prevention in low-resource settings. Clin Obstet Gynecol. 2013;56:76–87.
9. Celentano DD, Klassen A, Weissman CS, Rosenhein NB. The role of contraceptive use in cervical cancer: the Maryland cervical cancer case–control study. Am J Epidemiol. 1987;126:592–604.
10. Berry G, Maclennan R, Shearman R, Jelihovsky T, Booth JC, Molina R, et al. Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study. Int J Cancer. 1993;55:228–36.
11. Herrero R, Brinton LA, Reeves WC, Bennes MM, De Britton RC, Tenorio F, et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer. 2006;6:465–7.
12. Brinton LA. Oral contraceptives and cervical neoplasia. Contraception. 1991;43:581–95.
13. Dekissia, et al. Prevalence and factors associated with VIA positive result among clients screened at Family Guidance Association of Ethiopia, south west area office. Jimma model clinic. Jimma, Ethiopia 2013: a cross-sectional study. BMC Res Notes. 2015;8:618.
14. Biswas LN, et al. Sexual risk factors for cervical cancer among rural Indian women: a case–control study. Int J Epidemiol. 1997;26(3):491–5.
15. Chiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368–83.
16. Misgina KH, Belay HS, Abrahra TH. Prevalence of precancerous cervical lesion and associated factors among women in North Ethiopi. J Public Health Epidemiol. 2017;9(3):46–50.
17. Maluka JD, et al. Prevalence of risk factors for cervical cancer and precancerous lesions in Rwanda. Pan Afr Med J. 2015;22:26.
18. Deacon JM, Evans C, Yule R. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected? A case–control study nested within the Manchester cohort. Br J Cancer. 2000;88(11):1565–72.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit